Latest news with #PacificBiosciencesofCalifornia
Yahoo
29-07-2025
- Business
- Yahoo
Pacific Biosciences (PACB) Jumps 6.5% Ahead of Earnings
We recently published . Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the best-performing stocks on Monday. Pacific Biosciences jumped by 6.49 percent on Monday to close at $1.64 apiece as investors began repositioning portfolios ahead of its second-quarter earnings release. According to the company, it is scheduled to announce the results of its financial and operating highlights after market close on August 7, where investors will closely watch out for updates on its restructuring plan in a bid to reduce operating expenses by $45-$50 million by the end of the year. An investor call will be held on the same day to elaborate on the results. In the first quarter of the year, Pacific Biosciences of California, Inc. (NASDAQ:PACB) widened its net loss by 446 percent to $426 million from $78 million in the same period last year, following a 429-percent expansion in operating loss. Revenues amounted to $37.1 million, lower by 4.6 percent than the $38.8 million year-on-year. While we acknowledge the potential of PACB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
03-07-2025
- Business
- Yahoo
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, and emphasized the promise of its long-read sequencing technology. Financially speaking, Pacific Biosciences of California (NASDAQ:PACB) reported that its consumable revenue in Q1 2025 reached a record $20.1 million, a 26% increase from the previous year. Additionally, by improving its gross margin, cutting operational costs, and increasing top-line growth, the company targets profitability by 2027. Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and epigenetics. By using its PacBio Sequel System, the company also developed a novel enrichment method for targeted SMRT sequencing. This greatly improves sequencing efficiency by using the CRISPR-Cas9 system to do away with the necessity for PCR amplification. While we acknowledge the potential of PACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-04-2025
- Business
- Yahoo
Positive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past year
Given the large stake in the stock by institutions, Pacific Biosciences of California's stock price might be vulnerable to their trading decisions The top 7 shareholders own 52% of the company Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To get a sense of who is truly in control of Pacific Biosciences of California, Inc. (NASDAQ:PACB), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 85% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. After a year of 57% losses, last week's 11% gain would be welcomed by institutional investors as a possible sign that returns might start trending higher. Let's delve deeper into each type of owner of Pacific Biosciences of California, beginning with the chart below. View our latest analysis for Pacific Biosciences of California Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Pacific Biosciences of California does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Pacific Biosciences of California's historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. We note that hedge funds don't have a meaningful investment in Pacific Biosciences of California. The company's largest shareholder is ARK Investment Management LLC, with ownership of 12%. BlackRock, Inc. is the second largest shareholder owning 8.3% of common stock, and Madrone Advisors, Llc holds about 7.9% of the company stock. We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our most recent data indicates that insiders own less than 1% of Pacific Biosciences of California, Inc.. It has a market capitalization of just US$405m, and the board has only US$3.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. The general public, who are usually individual investors, hold a 14% stake in Pacific Biosciences of California. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It's always worth thinking about the different groups who own shares in a company. But to understand Pacific Biosciences of California better, we need to consider many other factors. For example, we've discovered 3 warning signs for Pacific Biosciences of California that you should be aware of before investing here. Ultimately the future is most important. You can access this free report on analyst forecasts for the company . NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
30-01-2025
- Business
- Yahoo
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the 'PacBio Q4 Earnings Call.' About PacBio Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Contacts Investors: Todd Friedmanir@ Media:pr@ in to access your portfolio
